MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Teva Pharmaceutical Industries Ltd.

Slēgts

SektorsVeselības aprūpe

14.71 2.94

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

14.17

Max

14.76

Galvenie mērījumi

By Trading Economics

Ienākumi

162M

-275M

Pārdošana

-103M

4.2B

EPS

0.71

Peļņas marža

-6.503

Darbinieki

33,892

EBITDA

51M

261M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+62.09% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

16B

Iepriekšējā atvēršanas cena

11.77

Iepriekšējā slēgšanas cena

14.71

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

Teva Pharmaceutical Industries Ltd. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2024. g. 17. dec. 19:39 UTC

Galvenie tirgus virzītāji

Correction to Teva Articles

2024. g. 17. dec. 16:24 UTC

Galvenie tirgus virzītāji

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

2024. g. 17. dec. 16:14 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Nvidia, Tesla, Broadcom, Pfizer, EVgo, Teva, SolarEdge, Affirm, and More -- Barrons.com

2024. g. 17. dec. 13:51 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Nvidia, Tesla, Broadcom, Pfizer, EVgo, Teva, SolarEdge, Red Cat, and More -- Barrons.com

2024. g. 23. nov. 12:00 UTC

Top Ziņas

Emerging-Markets Stocks Have Rarely Been So Hated. It's Time To Buy -- WSJ

2024. g. 22. aug. 05:30 UTC

Top Ziņas

Generic Weight-Loss Drugs Won't Come for Years -- Barrons.com

2024. g. 7. maijs 20:30 UTC

Top Ziņas

Teva Earnings Are Soon. What Could Keep the Stock Gains Going. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Teva Pharmaceutical Industries Ltd. Prognoze

Cenas mērķis

By TipRanks

62.09% augšup

Prognoze 12 mēnešiem

Vidējais 23.86 USD  62.09%

Augstākais 30 USD

Zemākais 20 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Teva Pharmaceutical Industries Ltd. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

7

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

13.44 / N/AAtbalsts un pretestība

Īstermiņā

Very Strong Bullish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.